Various media channels have commented on a study on cirrhosis performed by Raúl Méndez, ICREA researcher at IRB Barcelona, and Mercedes Fernández, at IDIBAPS, and published in Gastroenterology, the most prominent science journal in the field of gastrointestinal diseases. In their article, they show that the protein CPEB4 could serve as a therapeutic target to prevent the development of pathological blood vessels near the liver. The formation of these vessels is one of the most severe complications in cirrhosis patients and a key factor in the development and exacerbation of the disease.
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to offer pioneering solutions to unresolved medical needs in cancer and other diseases related to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).